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CHAPTER 1: INTRODUCTION 
1.1  The AID/APOBEC family  
The AID and APOBEC family of proteins catalyze the deamination of cytosines to 
uracils in single stranded DNA and/or RNA. They all share a conserved zinc binding 
domain, His-X-Glu-X25-31-Pro-Cys-X2-4-Cys. (X is any amino acid). The zinc (Z)-
coordinating motif is important in cytosine deamination. They possess either one or two of 
these domains (highlighted in Figure 1). Humans have seven APOBEC3 members.  
 
Figure 1: Members of the AID/APOBEC family of enzymes in higher vertebrates.  
                The zinc-binding domain is highlighted. 
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 APOBEC1 was the first enzyme to be identified in this family of enzymes, which plays 
an essential role in lipid metabolism [1, 2]. APOBEC1 introduces a premature translation 
termination codon in the pre-mRNA of Apolipoprotein B100, producing a shorter version, 
namely, Apolipoprotein B48. The two versions have differential activities regulating 
lipoproteins in liver. Mammalian APOBEC1 acts on RNA, but as discovered by Harris et 
al. in 2002, it can also act on single stranded DNA [3]. 
AID was the second member to be identified in this family by Muramatsu et al. in 
1999 [4]. It deaminates cytosines in single stranded DNA [3, 5]. AID plays a remarkable 
role in adaptive immunity in higher vertebrates. Specifically, AID is essential for antibody 
diversification and for the genearation of high affinity antibodies. In B cell immunoglobulin 
genes, AID introduced uracils are processed in different DNA repair and recombination 
pathways leading to class switch recombination and somatic hypermutation [6, 7]. These 
processes are essential in  efficient immune defense against pathogens. 
 
1.2 APOBEC3 sub-family 
Over the past 100 million years, APOBEC enzymes have evolved as a protective 
mechanism of immunity to prevent viruses and pathogens from infecting the organisms. 
The ancestral zinc binding deaminase domain has duplicated several times in humans 
within 150 kb in chromosome 22. This duplication encodes several APOBEC3 proteins [8]. 
The human APOBEC3 family consists of seven members, containing one or two zinc 
binding deaminase domains, namely, APOBEC3A-APOBEC3H. Primates also have 
multiple APOBEC3 genes that have undergone expansion and duplication, while rodents 
have a single APOBEC3 gene in their genomes [9]. The importance of this expansion of 
the APOBEC3 genes may be implicated in the protective function of restricting evolving 
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endogenous and exogenous retroviruses or retroelements in these higher organisms. 
More specifically, APOBEC3 enzymes are potent inhibitors of replication of exogenous 
retroviruses such as HIV-1 [10] although with varying levels [11, 12].  
 
 
Figure 2: The arrangement of the APOBEC3 genes in human chromosome 22. 
                  
 
1.3 Mouse APOBEC3 enzyme 
In contrast to humans, mice have one APOBEC3 gene. It is located in 
chromosome 15 which is syntenic to human chromosome 22 [13]. This gene encodes for 
a double domain DNA cytosine deaminase. In contrast to human APOBEC3G, where only 
the CTD is catalytically active, the NTD is catalytically active in mouse APOBEC3. The 
NTD is thought to be necessary for encapsidation of this enzyme into retroviruses. It 
shares ~33% sequence similarity with human APOBEC3G [14, 15]. Mouse APOBEC3 is a 
powerful restrictor of vif-deficient HIV-1, and the efficiency of restriction is comparable to 
that of the human APOBEC3G. Mouse APOBEC3 can introduce high levels of G to A 
mutations in the HIV-1 genome; hence the mechanism of restriction is deaminase 
dependent [16]. On the other hand, its ability to restrict murine retroviruses, such as MLV 
is limited compared to human APOBEC3G [17]. In biochemical terms, purified mouse 
APOBEC3 is capable of deaminating cytosine in short single stranded DNA, preferably 
towards the 3’ end [16]. Mouse APOBEC3 is expressed widely in lymphoid tissue. Despite 
the useful role played by mouse APOBEC3, it is not essential for the survival or 
development of mice [18]. 
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1.4 Human APOBEC3 enzymes 
APOBEC3A is a single domain DNA cytosine deaminase, which is implicated in its 
potential for restricting a myriad of retroviruses including HIV-1 [19, 20]. APOBEC3A has 
also has the potential to restrict certain DNA viruses such as HPV [21] and parvovirus 
[22]. Overexpressed APOBEC3A is capable of translocating to the nucleus and inducing 
genomic DNA damage [23]. However, Harris et al. suggested that endogenous 
APOBEC3A is cytoplasmic and incapable of genomic DNA editing [24]. Recently, it was 
also suggested that APOBEC3A can act as a foreign DNA restricting enzyme in 
mammalian cells [25]. In addition to DNA cytosine deaminase activity, APOBEC3A is 
efficient in deaminating 5-methylcytosines, suggesting a possible role in epigenetic gene 
regulation [26, 27]. APOBEC3A is a myeloid specific enzyme and type-1 interferon can 
increase its expression 10-1000 fold [19], consistent with its antiretroviral activity. 
APOBEC3B contains two conserved zinc binding cytosine deaminase domains. Several 
recent studies have shown that it is an enzymatic source of mutations in several human 
cancers, including breast cancer [28, 29]. It is the only APOBEC3 enzyme with nuclear 
localization [29].  Although there is no crystal or NMR structures available, APOBEC3B 
has been studied extensively as it can be targeted by anticancer drugs. APOBEC3C 
contains one zinc binding cytosine deaminase domain, and is implicated in HBV [30, 31] 
and SIV [32] restriction. A high resolution crystal structure of full length APOBEC3C was 
determined recently [33]. APOBEC3D, which was previously termed, APOBEC3DE is a 
moderately potent HIV-1 inhibitor in T cells.  In contrast, it is a potent inhibitor of Alu 
retrotransposition. As discussed below, APOBEC3D evolved under positive selection with 
loss of function mutations [34]. APOBEC3F contains two zinc binding domains. A high 
resolution crystal structure of the catalytically active APOBEC3F CTD is available [35]. 
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APOBEC3F is capable of restricting vif deficient HIV-1 but it is susceptible to vif mediated 
degradation [36, 37]. Vif is a HIV-1 encoded viral accessory protein that binds APOBEC3 
proteins and targets them for degradation, through ubiquitin proteasome pathway. 
APOBEC3G is the most studied and well characterized member of the APOBEC3 family 
of enzymes. The crystal structure of the catalytically active CTD of APOBEC3G was first 
established by Holden et a.l in 2008 [38]. The protein was purified from E.coli as a GST 
fusion. The NMR structure of the CTD of APOBEC3G was also published, but in a more 
soluble mutant form (2K3A) [39]. Numerous studies show that APOBEC3G possess very 
efficient HIV-1 restriction potential, but similar to APOBEC3F, it is susceptible to vif-
mediated degradation [40, 41]. 
The structures of the APOBEC3 deaminase domains provide insight into the 
mechanisms and the activity of the APOBEC3 enzymes and the substrate specificity of 
these proteins. APOBEC3 enzymes are emerging as targets of potential anti-cancer and 
anti-retroviral drugs. Furthermore, the residues of APOBEC3 enzymes that are involved in 
HIV-1 vif binding need to be studied.  In addition, to study the mechanism underlying 
retroviral restriction by APOBEC3 proteins and to understand their role in innate immunity, 
high resolution crystal or NMR structures would be useful. Unfortunately, some of these 
enzymes are insoluble and tend to precipitate in high concentrations as the molecules 
tend to aggregate [42]. Up to now, several groups were able to obtain the structures of the 
APOBEC3G CTD [39, 42], APOBEC3C [33], APOBEC3A  [43] and C-terminal domain of 
APOBEC3F [35]. APOBEC3H was the focus of my studies is described below.  
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1.5 HIV-1 restriction by APOBEC3 proteins 
To explain the mechanism of HIV-1 restriction by APOBEC3 enzymes, 
APOBEC3G is taken as the example. Vif-deficient HIV-1 virus infects human CD4+ T 
cells. APOBEC3G is expressed exclusively in the cytoplasm of these cells [41, 44]. To 
restrict HIV-1 replication and infection, APOBEC3G is first packaged into the viral core 
[41]. Once the virus particle infects a new target cell, APOBEC3G plays its role in viral 
restriction. HIV-1 begins to reverse transcribe the RNA genome to the cDNA intermediate 
which is the target for APOBEC3G [45]. The enzyme deaminates cytosines to uracils in 
this minus strand cDNA, which leads to degradation of the product. On the other hand, the 
uracil-rich cDNA undergoes synthesis of the second DNA strand (plus strand), generating 
G to A hypermutations in the pro-viral genome, which is detrimental for the replication of 
the virus [41, 45]. Virally encoded vif protein is capable of interacting with APOBEC3G 
and targeting it to ubiquitin proteasome mediated degradation [40].  
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Figure 3: Mechanism of retroviral restriction mediated by APOBEC3 enzyme. 
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1.6 APOBEC3H enzymes 
During host and pathogen protein interactions, evolution plays a key role in 
domination of either the host or the pathogen. This phenomenon is observed in the 
evolution of APOBEC3 proteins [46]. As APOBEC3 proteins are involved in restricting 
retroviruses, the evolution of the viral proteins that counteract the action of APOBEC3 also 
show strong positive selection [47]. At the same time, host defensive proteins, such as 
APOBEC3 enzymes, have undergone multiple diversifications and duplications to better 
counteract viral replication in cells. APOBEC3H evolved from ancestral genes at least 33 
million years ago during primate evolution [48]. 
The human APOBEC3H gene is located downstream of APOBEC3G. It contains a 
single zinc binding domain. The function of APOBEC3H is poorly characterized. The 
presence of conserved a cytosine deaminase domain suggested that APOBEC3H might 
play a role in genome defense. It shares much less amino acid sequence similarity to 
other single domain cytosine deaminase, APOBEC3A (~29.6%) and APOBEC3C 
(~34.6%). APOBEC3H mRNA was detected in peripheral blood mononucleated cells 
(PBMC), testis, ovary and skin [48]. Also, the mRNA level of human APOBEC3H was 
upregulated >22-fold upon stimulation with interferon in CD4+ T cells [49]. Primate 
APOBEC3H consists of an evolutionarily distinct cytosine deaminase domain [9]. It is 
considered as the most evolutionarily divergent APOBEC3 protein and evolved under 
strong positive selection. Previously it was not identified as a retroviral restriction factor in 
primates, but the position of the APOBEC3H gene proximal to APOBEC3G and the 
possession of the conserved zinc binding deaminase domain, lead the researchers to 
investigate its potential in innate immunity and for the retroviral restriction. Until the whole 
genome sequencing project was completed, APOBEC3H was not identified as a cytidine 
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deaminase [9, 13]. APOBEC3H of OWMs, such as macaques, possess strong restriction 
activity against primate lentiviruses, for example, HIV-1 and SIV [48]. In contrast, the 
protein expression of human APOBEC3H was poor in primate cells and shows much less 
restriction ability of retroviruses compared to OWM APOBEC3H [48]. Of note, human 
APOBEC3H was unable to  restrict vif-deficient HIV-1 [48]. In contrast, feline APOBEC3H 
is a potent inhibitor of HIV-1 and induced G to A mutations in HIV-1 genome [50]. Despite 
the low levels of human APOBEC3H proteins detected in the transfected cells, mRNA 
levels were comparable to the level detected in OWM. By successfully expressing OWM 
and human APOBEC3H in bacteria, OhAinle M. et al. [51] demonstrated that both proteins 
show DNA cytosine deaminase activity. Using a bacterial rifampicin resistance assay, 
human APOBEC3H was shown to cause ~6.1-fold increase in mutation frequency, while 
macaque APOBEC3H caused a ~3.1-fold increase over background. By sequencing the 
rpoB gene, a significant increase of G to A mutations was detected, confirming both 
human and macaque APOBEC3H are proficient in deaminating cytosines in DNA. In 
contrast, mammalian cells overexpressing human APOBEC3H were used to obtain HIV-1 
proviruses, the viral genome did not carry any detectable G to A mutations; however a 
significant hypermutation was observed in viral genomes obtained from cells expressing 
macaque APOBEC3H and human APOBEC3G [48]. 
The weak HIV-1 restriction potential of human APOBEC3H was attributed to its 
poor expression in primate cells, although it is an active deaminase. Evidence for its 
potential to mutate the genome of DNA viruses, such as HBV [31] and HPV [21]  suggest 
that human APOBEC3H is active in mammalian cells. In order to investigate the 
underlying cause for the reduced HIV-1 restriction potential and poor expression of human 
APOBEC3H  in cell culture, Dang Y. et a.l [52] compared the amino acid sequences of 
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several primate APOBEC3H enzymes. Macaque APOBEC3H is 210 amino acids long. 
The presence of a premature termination codon in the last (fifth) exon in both human and 
chimpanzee APOBEC3H results in a truncated version in these organisms [52]. The 
premature termination codon in human APOBEC3H causes a 29 amino acid deletion from 
the C-terminal end. Loss of these amino acids was attributed to the significantly lower 
levels of this protein in cells [52]. This deletion was not seen in APOBEC3H genes of 
macaque and African green monkey.  The mRNA level of this shortened APOBEC3H was 
reduced drastically even though the protein stability was unaffected [52]. Interestingly, 
restoration of the truncation by repairing the termination codon or increasing the 
expression of APOBEC3H under the control of a strong promoter, showed increased 
protein expression. The restored or optimally expressed APOBEC3H showed potent anti 
HIV-1 and SIV restriction potential [52]. In addition, the authors propose that HIV-1 vif was 
capable of counteracting the restriction, only when APOBEC3H was expressed well. The 
barely detectable levels of G to A hypermutations in the HIV-1 genome suggests that 
although human APOBEC3H is capable of restricting HIV-1, the mechanism is 
deamination independent. [52].   
To further investigate the reasons for the loss of anti-retroviral activity of human 
APOBEC3H, OhAinle M. et al. [51] analyzed the evolution of the activity of hominoid 
APOBEC3H enzymes. The reconstructed ancestral human APOBEC3H sequence, which 
showed potent antiretroviral activity, was lost due to two independent polymorphisms that 
destabilized the protein [51]. The amino acid mutations R105G or ΔN15 contributed to 
decrease the half life of the protein. Although the majority of the human population 
showed a reduced amount of stable APOBEC3H expression, hence no antiretroviral 
activity, individuals of African descent stably express APOBEC3H. Cells from African 
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populations are capable of inhibiting HIV-1 and LINE-1 retrotransposition [51]. Similar to 
the ancestral APOBEC3H, this allele does not contain the destabilizing mutations and is 
sensitive to HIV-1 vif. This suggests that the evolution of human APOBEC3H is under 
strong negative correlation with its potential to restrict retroviruses, presumably because 
of the evolution of many other retroviral restriction factors in human cells or more 
functionally proficient APOBEC3 enzymes. As explained below, the population specific 
variation in the stability of human APOBEC3H is identified due to the presence of multiple 
substitution mutations in the gene in different human lineages.  
Interestingly, multiple polymorphisms exist naturally in human APOBEC3H. 
Primarily, the G105R, K121E and E178D cluster of substitution mutations are observed in 
African populations frequently, but are considerably less common in Asian and European 
populations [53]. This cluster, not the wild type, has shown restriction potential against 
HIV-1, Alu and non-LTR LINE-1 retrotransposition [54].  The observation that this  
APOBEC3H variant expresses well in mammalian cells compared to wild type was 
attributed to its highest potential in HIV-1 restriction. In short, the variants of APOBEC3H 
show different levels of restricting retroviruses and retrotranpositions. Harari et al. 
continued to study the polymorphisms that exist in the human APOBEC3H population and 
found that  more APOBEC3H variants exist in the human population [53]. 
As explained below, several groups have also provided evidence for the existence 
of multiple APOBEC3H variants in human tissues and cells. Additionally, the degree of 
antiretroviral activity against HIV-1 and resistance to vif is assessed in several findings. 
Harari et al. [53] studied APOBEC3H cDNA obtained from peripheral blood 
mononuclear cells (PBMC) of twelve HIV-1 negative healthy blood donors. Four different 
APOBEC3H genetic variants were identified in these donors. HapI-GKE served as the 
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wild type reference sequence, (NM_181773) where G, K and E are the amino acids at 
positions at 105, 121 and 178 in human APOBEC3H. The nonsynonymous substitution 
mutations at amino acid positions at this positions; G105R, K121D and E178D produce 
the second haplotype of human APOBEC3H, denoted HapII - RDD. Moreover, two 
additional haplotypes were identified in these cells [53]. Hap II - RDD with Δ15N is 
denoted as haplotype III. Hap II - RDD with Δ15N and L18R is denoted as haplotype IV. 
The four major haplotypes are expressed in a population dependent manner. Additional 
APOBEC3H genetic variants are listed in the Single Nucleotide Polymorphism database 
at NCBI. (www.ncbi.nlm.nih.gov/projects/SNP). These are one synonymous substitution 
mutation at codon 43, two deletions (Δ14 and Δ15) and several nonsynonymous 
mutations (R18L, G37H, G105R, K121E/N, S140G, and E178D). Haplotype I was the 
most abundant variant of APOBEC3H as it was present in 10 out of 12 blood donors [53]. 
The alternative splicing of human genes plays an important role in the functions of 
the gene products leading to diverse and varying enzyme amounts and activities in cells. 
In addition, the expression profiles and the levels of the splice variants may differ, in a cell 
or tissue specific manner. Sometimes the expression profile reflects the function of the 
variant [55]. In addition to the human APOBEC3H haplotypes, four different splice variants 
were found in the human blood cells, namely sv-154, sv-182, sv-183 and sv-200 [53]. The 
numbers denote the length of the proteins in amino acids. 
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Figure 4: Representation of the four major splice variants of human APOBEC3H. 
                CDD: cytosine deaminase domain. 
  
All the splice variants share exons 2, 3 and 4, except sv-154, which has skipped 
exon 4 but contains the cryptic exon 4b. In addition to exon 4, sv-200 has the cryptic exon 
4b. sv-182 is devoid of the glutamine in exon 5, that is found in sv-183 (Figure 4). The four 
splice variants are comprised of SNPs that are described above. From the genomic 
sequences of the transcript variants, it can be concluded that human APOBEC3H is highly 
diverse and contains multiple haplotypes and splice variants that have distinct C-terminal 
domains. Harari et al. [53] compared the potential of inhibiting HIV-1 by all the variants of 
human APOBEC3H. They observed that the splice variants of hapII-RDD was more 
powerful and uniform in restricting HIV-1 than hapI-GKE, as the splice variants of hapI-
GKE showed varying levels of antiretroviral ability.  But, the sv-183 of hapI-GKE showed 
20-fold more restriction potential than background, which was the level of restriction 
observed by APOBEC3G. This result suggests that sv-183 of HapI-GKE has greater 
potential in restricting  HIV-1 replication in mammalian cells [53]. 
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Figure 5: Human APOBEC3H splice variants from ENSEMBL genome browser 
 
 
 
Figure 6: Four splice variants of human APOBEC3H found in PBMCs 
    (sv-183, sv-182, sv-200 and sv-154). They contain distinct C-terminal domains     
    The CDD is underlined. In purple, the unique C-terminal domains are indicated. 
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Although APOBEC3H is distinct from other APOBEC enzymes in humans, it 
closely resembles the CTD of mouse APOBEC3 [9]. Mouse APOBEC3 is sensitive to HIV-
1 vif and the restriction potential of mouse APOBEC3 against HIV-1 is comparable to that 
of human APOBEC3G [53]. Harari et al. [53] and several other groups [56, 57] have 
confirmed that human APOBEC3H is also HIV-1 vif resistant. To study the underlying 
mechanism of the resistance to HIV-1 vif by human APOBEC3H, Li et al. [57] compared 
the level of susceptibility of APOBEC3H to several vif proteins cloned from HIV-1 infected 
patients with different APOBEC3H genotypes. The SNP K121D in hap-II has been 
identified as the major determinant for conferring resistance against HIV-1 vif, as hapII-
RDD has increased antiretroviral activity against HIV-1, consistent with previous studies 
[53, 57]. Interestingly, change of lysine at position 121 to an acidic amino acid increased 
susceptibility to HIV-1 vif. Using novel antibodies to detect untagged human APOBEC3H, 
instead of identifying tagged versions, they observed that the hap-I conferred low 
resistance to HIV-1, as did splice variants of hap-III and hap-IV [57]. Consistent with 
previous studies, hap-II was highly expressed than the other variants, and showed 
increased potential in restricting vif deficient HIV-1. In contrast to the previous studies, by 
directly comparing protein levels with and without HIV-1 vif, Zhen et al. [56] proposed that 
hap-II is susceptible to HIV-1 vif, although hap-I is completely resistant to proteasomal 
degradation. Studying a panel of vif mutants, they suggested that, apart from the motifs in 
vif that are involved in interacting with APOBEC3G and APOBEC3F, additional motifs of 
vif were identified in interacting with APOBEC3H hap-II. After obtaining similar expression 
levels for both hap-I and hap-II, Zhen et al. [56] observed that both the variants had similar 
virion packaging levels and antiretroviral activity against HIV-1. As the mutant hap-I 
G105R was more stable than the hap-I variant, and showed increased steady state 
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protein levels, it can be concluded that residue 105 is critical for the stability of the protein 
[56]. Introduction of this positively charged residue at this position might increase its 
solubility or provide a suitable interaction surface for an accessory factor that increases its 
stability as this residue is exposed to the surface (From modeling with APOBEC3G-NTD 
and APOBEC2 structure). 
Ooms et al. [58] proposed a different phenomenon to explain the varying levels of 
antiretroviral activity between hap-I and hap-II. The localization of the APOBEC3H 
variants within the egressing HIV-1 virion was considered as the vital factor, not protein 
expression levels. Hap-II RDD interacted with the nucleocapsid part of the Gag protein in 
the virion, in an RNA dependent manner; whereas hap-I GKE interacted with the C-
terminal of the capsid. The high affinity of the hap-II variant to host RNA resembles 
APOBEC3G, as APOBEC3G is incorporated to the virion in an RNA dependent manner. 
As hap-II RDD is proficient in restricting HIV-1, its ability to interact with the nucleocapsid 
part of the Gag protein was considered to be the major determinant. In contrast, hap-I did 
not show any RNA binding or HIV-1 restriction [59]. The W115 residue of hap-II RDD was 
crucial for the RNA binding ability [59].  The deletion of N15 in hap-III and hap-IV is 
implicated in its reduced affinity to RNA. Using a rifampicin resistance assay, Ooms et al. 
[58] observed that the APOBEC3H variants have comparable DNA cytosine deaminase 
activities, but the activity correlated with the expression in E. coli. 
Wang et al. [60] in 2011 identified three novel SNPs in six different human 
populations, in addition to the N15Δ, R18L, G105R, K121D and E178D, discussed above. 
The new polymorphisms are named hap-V (N15, R18, R105, D121, E178), hap-VI (N15Δ, 
L18, G105, K121, D178) and hap-VII (N15, R18, R105, K121, E178). Hap-V and VII 
expressed high levels of proteins in the steady state and restricted HIV-1 replication. From 
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the studies on hap-VII, the motif, YYXW (residues 112-115) was identified to be critical for 
the interaction with the HIV-1 nucleocapsid, hence virion packaging.  The Y112A mutation 
completely abolished the incorporation of APOBEC3H into HIV-1 virions.  Replacement of 
the corresponding region of APOBEC3H with the motif crucial for the vif interaction from 
APOBEC3G did not increase the vif sensitivity of APOBEC3H [60]. 
  Li et a.l [61] discovered that human APOBEC3H hap-II prefers cytoplasmic localization, 
similar to macaque APOBEC3H, whereas hap-I is primarily retained in the nucleus. The 
exclusive localization of hap-II in the cytoplasm is attributed to its interaction with host 
factors that are necessary for HIV-1 restriction. As retroviral reverse transcription occurs in 
the cytoplasm, the APOBEC3 enzymes must be located there to do this job. Hap-I GKE is 
translocated to the nucleus by passive diffusion. The putative NES at the C-terminal of the 
ancestral primate APOBEC3H has been lost due to mutations [61]. Truncation of the C 
terminal region of the NES in humans and chimpanzee APOBEC3H was observed later in 
evolution, leading to increased nuclear localization of the APOBEC3H variants, and 
reducing antiretroviral activity. The single mutation G105R was sufficient to change from 
nuclear to cytoplasmic localization for hap-I GKE [61]. A summary of antiviral activity, vif 
sensitivity, and the distribution profiles of the human APOBEC3H haplotypes and its splice 
variants are shown in Table 1. 
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APOBEC3H 
haplotypes/ 
splice variants 
Antiviral activity Vif sensitivity Remarks 
Ancestral human 
APOBEC3H 
(G105R, N15) 
Restrict HIV-1, LINE-1, 
Alu [51] 
Sensitive to HIV-1 
vif [51] 
African 
populations  
hapII-RDD Inhibit non-LTR LINE-1 
[54], Alu[54] 
retrotransposition, strong 
HIV-1 restriction [53, 56-
58, 62] 
All variants 
resistant to HIV-1 
vif [53], completely 
sensitive to HIV-1 
vif [56] 
Prevalent in 
Africans [57, 60] 
hap I –GKE sv-
183 
WT HIV-1 restriction 
comparable to 
APOBEC3G [53], weak 
anti HIV-1 activity [57, 
58] 
HIV-1 vif resistant 
[53, 57], sensitive 
to HIV-2 vif [57] 
 
hap II-RDD sv-
183 
WT HIV-1 restriction 
higher than APOBEC3G 
[53], powerful anti HIV-1 
Δvif activity [57, 61] 
HIV-1 vif resistant 
[53], Somewhat 
sensitive to HIV-1 
vif [57], sensitive 
to HIV-2 vif [57] 
 
hap I –GKE sv-
182 
Poor restriction of HIV-1 
than hap I –GKE sv-183 
[53] 
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APOBEC3H 
haplotypes/ 
splice variants 
Antiviral activity Vif sensitivity Remarks 
hap I –GKE sv-
200 
Poor restriction of HIV-1 
than hap I –GKE sv-183 
[53] 
  
hap II –RDD sv-
182 
Higher restriction of HIV-
1 than hap II- RDD sv-
183 [53] 
  
hap II –RDD sv-
200 
Higher restriction of HIV-
1 than hap II- RDD sv-
183 (comparable to 
APOBEC3G)  [53] 
HIV-1 vif resistant 
[53] 
 
hap - III sv-183 No HIV-1 restriction [57]   
hap – IV sv-183 No HIV-1 restriction [57]   
hap – V sv-183 Restrict HIV-1[60]  African-
American, 
Chinese 
populations[60] 
hap – VII sv-183 Restrict HIV-1[60]  European 
Caucasian[60] 
 
Table 1: Summary of activity and distribution of human APOBEC3H 
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Despite biological functions such as retroviral restriction and inhibition of 
retrotransposition, the biochemical properties and the enzyme kinetics of human 
APOBEC3H are currently unknown. Also a high resolution crystal or NMR structure with 
or without DNA substrate bound is not yet available for any of the variants of human 
APOBEC3H. In order to obtain biochemically valid kinetic parameters, homogeneous 
preparation of the active form of the enzyme is required. The question of structure-activity 
relationships in various haplotypes can be addressed from a valid crystal or NMR 
structure. In addition, the residues that are important for interactions with HIV-1 vif in 
different variants can also be determined by suitable crystal structures with vif. Finally, 
homogeneous preparations of human APOBEC3H protein variants are crucial for 
analyzing and confirming the activity profile observed in biological studies.  
 In the Ensembl Genome Browser (accessed March 2014), four protein coding 
human APOBEC3H variants are found. The gene identity is ENSG00000100298. For this 
study, I used two hapI-GKE splice variants that encode 200 and 183 amino acid proteins. 
The DNA cytosine deaminase activity was compared between the two variants using both 
an E. coli based genetic reversion assay and an in vitro DNA cytosine deamination activity 
assay which was carried out using purified APOBEC3H.   
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CHAPTER 2: MATERIALS AND METHODS 
 
2.1 Cloning of human APOBEC3H 
A cDNA clone of human APOBEC3H hapI-GKE sv-200 (NCBI sequence 
NM_001166003) was purchased from OriGene Technologies (Rockville, MD) and used as 
the template for cloning. All the clones that were generated were validated by sequencing. 
(The DNA Sequencing Core, University of Michigan, Ann Arbor). Plasmid extractions on a 
small scale were done using an E.Z.N.A.® Plasmid Mini Kit I (Omega Bio-Tek, Norcross, 
GA). 
The cDNA were cloned into the pACYC184-based expression plasmid pSU24 [63] 
to carry out the kanamycin resistance reversion assay (Figure 7). To clone the splice 
variant with 200 amino acids, the cDNA was amplified using the primers, pSUA3H200-F 
and pSUA3H200-R to introduce 5′ HindIII and 3’ EcoRI sites. To clone, APOBEC3H-183, 
the same template cDNA was used but was amplified with pSUA3H183-F and 
pSUA3H183-R and the same restriction sites were introduced. The resulting clones were 
named as pSUA3H-200 and pSUA3H-183, respectively.  
To purify the APOBEC3H-200 protein, an N-terminally GST tagged version was 
cloned (Figure 8). The cDNA for APOBEC3H hap I GKE sv-200 was cloned into pGEX4T3 
vector (GE Healthcare) as 5’ EcoRI and 3’ XhoI sites and named pGA3H200.  
To purify the APOBEC3H-183 protein, an N-terminally poly-histidine tagged 
version was generated (Figure 9). The cDNA for APOBEC3H hap I GKE sv-200 was used 
as template and amplified cDNA of sv-183. cDNA was cloned into pET28a+ vector 
(Novagen) as 5’ NdeI and 3’ XhoI sites and named  pETA3H183. 
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The primers used for cloning were custom synthesized by Sigma-Aldrich 
(Woodlands, TX). The sequences of the primers are listed in Table 2.  
 
Name of the 
oligonucleotide Sequence 
pSUA3H200-F 5’ GCG GCG GCG AAG CTT ATG GCT CTG TTA ACA GCC 
pSUA3H200-R 5’ GCG GCG GCG GAA TTC TCA TCA GAC CTC AGC ATC 
pSUA3H183-F 5’ GCG GCG GCG AAG CTT ATG GCT CTG TTA ACA GCC 
pSUA3H183-R 5’ GCG GCG GCG GAA TTC TCA TCA GGA CTG CTT TAT CCT 
pETA3H183-F 5’ GGC CGC CCA TAT GGC TCT GTT AAC AG 
pETA3H183-R 5’ GCG CGC GGA ATT CTC ATC AGG ACT GCT TTA TCC TCT C 
GSTA3H200-F 5’ GGG CCC GGG GAA TTC CGC TCT GTT AAC AGC CG 
GSTA3H200-R 5’ GGG CCC GGG CTC GAG TCA GAC CTC AGC ATC ACA 
CCC (6-FAM) 5' ATT ATT ACC CAT TTA TT 
CCU (6-FAM) 5' ATT ATT ACC UAT TTA TT 
ACC  (6-FAM) 5' ATT ATT AAC CAT TTA TT 
TCC (6-FAM) 5' ATT ATT ATC CAT TTA TT 
GCC  (6-FAM) 5' ATT ATT AGC CAT TTA TT 
 
Table 2: The oligonucleotide sequences. 
              6-FAM: 6-carboxyfluorescein  
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Figure 7: pSU24 plasmid map and MCS. 
                APOBEC3H splice variants were introduced as HindIII and EcoRI fragments.  
 
  
 
Figure 8: pGEX4T3 plasmid map and MCS. 
                  APOBEC3H-200 was introduced as an EcoRI and XhoI fragment. 
  
24 
 
 
 
 
 
 
Figure 9: pET28a+ plasmid map and MCS. 
                    APOBEC3H-183 was introduced as an NdeI and XhoI fragment. 
 
2.2 Purification of GST-APOBEC2H-200 
 The plasmid pGA3H200 was transformed into the E. coli strain BL21. Ten to 
twelve single colonies were inoculated into a single 5 mL of Luria Bertani (LB) medium 
culture  containing 50 μg/mL carbenicillin, which was grown overnight at 37 °C. A 1:1000 
dilution was performed from the overnight culture into 500 mL LB with carbenicillin. The 
cells expressing the protein were grown to mid-log phase with adequate aeration at 37 °C. 
The culture was cooled to 4 °C and expression was induced by adding IPTG (Gold 
Biotechnology) at a final concentration of 0.2 mM. The culture was grown overnight at 16 
°C with shaking. Cells were spun down using a Sorvall rotor at 8,000 rpm for 20 minutes 
at 4 °C. The cells were lysed using a French pressure cell press (Thermo Spectronic) in 
30 mL of 20 mM Tris-HCl, pH 8.0 and 50 mM NaCl containing a half a tablet of an EDTA 
free protease inhibitor cocktail. (Roche diagnostics, Indianapolis. IN). The lysate was 
clarified by centrifuging at 14,000 rpm for 20 minutes at 4 °C. The cleared lysate was 
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incubated with glutathione sepharose 4B beads (GE Healthcare) in a total column volume 
of 750 μL for 2 hours at 4 °C on a rotating platform. The lysate was allowed to settle and 
the flow through was collected. The beads were washed with 10 column volumes of buffer 
containing 20 mM Tris-HCl, pH 8.0 and 50 mM NaCl. The protein was eluted using buffer 
containing 50 mM Tris-HCl, pH 8.0 and 20 mM reduced glutathione (Sigma Aldrich); 1 mL 
fractions were collected. The cell free lysate (15 μL each), flow through, wash fractions 
and elution fractions were mixed with SDS-PAGE gel loading buffer (50 mM Tris-HCl, pH 
6.8, 100 mM DTT, 2% SDS, 0.1% bromophenol blue and 10 % glycerol).  The samples 
were heated at 95 °C for 5 minutes and briefly spun down. The soluble portion was loaded 
onto a 12% SDS-PAGE gel and ran at 100 V in 20mM Tris-HCl, 192 mM glycine and 0.1% 
SDS buffer. The gel was stained in Coomassie Brilliant Blue (BioRad) (1g/L), 50% 
methanol and 10% glacial acetic acid. The gel was destained using 50% methanol and 
10% glacial acetic acid. The fractions that contained the desired protein (expected size of 
GST-A3H200 is ~48 kDa) were dialyzed using 10 kDa molecular weight cut-off Slide-A-
Lyzer Dialysis Cassettes (Thermoscientific, Rockford, IL) in 20 mM Tris-HCl, pH 7.6, 50 
mM NaCl, 1 mM EDTA, 1 mM DTT and 10% glycerol at 4 °C overnight. The resultant 
protein preparation was concentrated using a 10 kDa molecular weight cut-off Amicon 
Ultra Centrifugal device (Milipore, Billerica, MA) by centrifuging at 4,000 g for 20-30 
minutes at 4 °C. The concentration of the final protein preparation was measured using 
Bradford reagent (Bio-Rad) against BSA standards from the absorption at 595 nm. Protein 
was aliquoted and stored at -20 °C until further use. For initial activity assays, 1 μg of the 
protein was used in each reaction. 
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2.3 Western Blotting of GSTA3H200 
To confirm the overexpression of GSTA3H200 in BL21 cells, a Western blot was 
carried out on the concentrated eluate obtained from the glutathione affinity column. 
Briefly, 20 μL of the elution fraction was mixed with of SDS-PAGE gel loading buffer (50 
mM Tris-HCl, pH 6.8, 100 mM DTT, 2% SDS, 0.1% bromophenol blue and 10 % glycerol). 
The content was mixed and heated at 95 °C for 5 minutes and briefly spun down. An 
aliquot of the soluble portion (15 μL) was loaded onto a 12% SDS-PAGE gel and ran at 
100V in 20 mM Tris-HCl, 192 mM glycine and 0.1% SDS.  
The proteins were electrophoretically transferred to a PVDF membrane (EMD 
Millipore) which had been presoaked in methanol. The transfer was carried out at 100 mA 
for two hours at 4 °C. The blot was incubated with the blocking buffer, 5% non-fat dry milk 
in 1X TBS-T (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.05% Tween-20) at 4 °C overnight. 
The blot was washed for 5 minutes three times with TBS-T and incubated with the rabbit 
anti-GST tag primary antibody (GeneScript) with a final concentration of 1 μg/mL at room 
temperature for two hours. The blot was washed again with TBS-T and was incubated 
with the secondary antibody, goat anti-rabbit antibody (AnaSpec) with a final 
concentration of 1 μg/mL at room temperature for one hour. The blot was washed again 
with TBS-T and scanned using Typhoon Phosphorimager (GE Healthcare) at the 
excitation wavelength of 633 nm under a red laser. 
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2.4 Kanamycin resistance reversion assay 
The E. coli based genetic assay was described before [64, 65]. Briefly, a defective 
kanamycin allele was used; in which 94th leucine residue was mutated to proline 
(kanamycin sensitive phenotype in E. coli).  After one round of replication, the 
deamination of cytosines to uracils in this codon will result in C to T mutations, restoring 
the kanamycin resistant phenotype. The number of C to T mutations is scored as the 
kanamycin resistance revertant frequency (Figure 10). Plasmids, pSUA3H-200 or 
pSUA3H-183 was cotransformed with the pUP31 plasmid into BH214 strain of E. coli 
which is a GM31 ung mug strain. The defective kanamycin allele is provided from pUP31 
[66, 67]. For the positive control, human APOBEC3A cloned into pSU24 (pSUA3A) was 
used [26]. The empty vector, pSU24, or the catalytically null mutant of human APOBEC3A 
cloned in pSU24 (pSUA3AE72A) [26] were used as negative controls. The 
cotransformants were selected by plating on an LB plate containing chloramphenicol (25 
μg/mL) and carbenicillin (50 μg/mL). LB medium (5 mL) with chloramphenicol (25 μg/mL) 
and carbenicillin (50 μg/mL) was inoculated with a single colony from the selective plate. 
The culture was grown overnight. A 1:1000 dilution of the overnight culture was carried 
out in LB containing the appropriate antibiotics and the culture was grown for two hours at 
37 °C with shaking.  For the experiments with IPTG induction, varying concentrations of 
IPTG were added to the cultures. The cultures were split into eight or more independent 
cultures (5 mL each). The cultures were grown until the mid-log phase (i.e. OD600 ~ 0.4 to 
0.6). The cultures were spread onto LB-agar plates with 50 μg/mL kanamycin to score the 
number of revertants. To score for the total number of viable cells, a 2.5 x 106 dilution of 
the cultures were plated on LB-agar plates containing 25 μg/mL carbenicillin. Kanamycin-
resistance revertant frequency was calculated as the ratio between the numbers of 
28 
 
 
 
kanamycin-resistant colonies to the total number of viable cells. The median values were 
calculated and analyzed using GraphPad Prism software. The Mann-Whitney t-test was 
used to calculate p-values. 
 
Figure 10: The basis of the kanamycin resistance reversion assay. 
 
2.5 Purification of poly-histidine tagged A3H-183 using nickel affinity  
The plasmid pETA3H183 was transformed into the E. coli strain BL21 (DE3). Ten 
to twelve single colonies were inoculated into a single 5 mL of LB medium culture  
containing 50 μg/mL kanamycin, which was grown overnight at 37 °C. A 1:1000 dilution 
was performed from the overnight culture into 500 mL LB with kanamycin. The cells 
expressing the protein were grown to mid-log phase with adequate aeration at 37 °C. The 
culture was cooled to 4 °C and expression was induced by adding IPTG (Gold 
Biotechnology) at a final concentration of 0.2 mM. The culture was grown overnight at 16 
°C with shaking. Cells were spun down using a Sorvall rotor at 8,000 rpm for 20 minutes 
at 4 °C. The cells were lysed using French pressure cell press (Thermo Spectronic) in 30 
mL of 20mM Tris-HCl pH 8.0, 50mM NaCl and 40mM imidazole (Sigma-Aldrich) 
containing a half a tablet of the EDTA free protease inhibitor cocktail. (Roche diagnostics, 
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Indianapolis. IN). The lysate was clarified by centrifuging at 14,000 rpm for 20 minutes. 
The cleared lysate was incubated with high affinity Ni-charged resin (GenScript) in a total 
column volume of 1 mL for one hour at 4 °C on a rotating platform. The lysate was 
allowed to settle and the flow through was collected. The beads were washed with 10-15 
column volumes of the buffer containing 20 mM Tris-HCl, pH 8.0, 40 mM imidazole and 50 
mM NaCl (wash 1). Wash was repeated with 20 mM Tris-HCl, pH 8.0, 40 mM imidazole 
with increasing NaCl concentrations (200 mM and 500 mM respectively) with each step. 
The wash steps were carried out until no detectable proteins were eluted in Bradford 
qualitative assay. These wash steps are indicated as wash 2 and 3 in Figure 16. The 
protein was eluted in 20 mM Tris-HCl, pH 8.0, 500 mM NaCl with 300 mM imidazole. 15 
μL of the cell free lysate, flow through, wash and elution fractions were mixed with SDS-
PAGE gel loading buffer.  The samples were heated at 95 °C for 5 minutes and briefly 
spun down. The soluble portion was loaded onto a 15% SDS-PAGE gel and ran at 100V 
in 20mM Tris-HCl, 192 mM glycine and 0.1% SDS buffer. The gel was stained in 
Coomassie Brilliant Blue (BioRad) (1g/L), 50% methanol and 10% glacial acetic acid. The 
gel was destained using 50% methanol and 10% glacial acetic acid. The fractions that 
contained the desired protein (expected size of His-A3H183 is ~23 kDa) were dialyzed 
using 10 kDa molecular weight cut-off Slide-A-Lyzer Dialysis Cassettes (Thermoscientific, 
Rockford, IL) in a step-wise manner. First, the dialysis was carried out in 20 mM Tris-HCl, 
pH 7.6, 200 mM NaCl, 1mM EDTA, 1mM DTT and 10% glycerol at 4 °C for 8-10 hours 
and it was repeated for another 8 hours, with the same buffer, except with a NaCl 
concentration of 50 mM. The resultant protein preparation was concentrated using 10 kDa 
molecular weight cut-off Amicon Ultra Centrifugal device (Milipore, Billerica, MA) by 
centrifuging at 4000 g for 20-30 minutes at 4 °C. The concentration of the final protein 
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preparation was measured using Bradford reagent against a standard series of BSA from 
the absorption at 595 nm. The protein was aliquoted and stored at -20 °C until further use. 
For initial activity assays, 1 μg of the protein was used in each reaction. 
 
2.6 Western Blotting of his-A3H183 
To confirm the overexpression of N-terminally poly-histidine tagged APOBEC3H-
183 in BL21(DE3) cells, a Western blot was carried out with the eluate and other fractions 
obtained from nickel affinity purification. Briefly, 17μL of the cell free lysate, flow-through, 
portions from the wash steps, and elution fractions were each mixed with SDS-PAGE gel 
loading buffer. The samples were mixed and heated at 95 °C for 5 minutes and briefly 
spun down. Aliquots of the soluble portion (15 μL) were loaded onto a 15% SDS-PAGE 
gel and ran at 100V in 20 mM Tris-HCl, 192 mM glycine and 0.1% SDS.  
The proteins were electrophoretically transferred the proteins to a PVDF 
membrane (EMD Millipore) which has been presoaked in methanol. The transfer was 
carried out at 100 mA for two hours at 4 °C. The blot was incubated with the blocking 
buffer, 1% BSA in 1X TBS-T (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.05% Tween-20) at 
room temperature overnight. The blot was washed for 5 minutes three times with TBS-T 
and incubated with the mouse anti-his tag primary antibody (AnaSpec) with a final 
concentration of 1 μg/mL at room temperature for two hours. The blot was washed again 
with TBS-T and was incubated with the secondary antibody, goat anti-mouse IgG (H+L), 
Hilyte FlourTM 647-labeled (AnaSpec) with a final concentration of 1 μg/mL at room 
temperature for one hour. The blot was washed again with TBS-T and scanned using a 
Typhoon Phosphorimager (GE Healthcare) at the excitation wavelength of 633 nm under 
a red laser.  
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2.7 Size exclusion chromatography of poly-histidine tagged A3H-183 
 A fresh preparation of overexpressed lysate was obtained from a 2 L culture, as 
described above in section 2.5. All growth and purification conditions were scaled-up 
accordingly. As the protein was active under the elution condition that was used in nickel 
affinity purification, the buffer containing 20 mM Tris-HCl, pH 8.0 and 500 mM NaCl was 
used to equilibrate the column. A total of ~0.8 mg of crude eluate from the nickel affinity 
column was used to load a HiLoad 16/600 Superdex 200 pg (GE Healthcare) size 
exclusion column. Fractions (2 mL) were collected at a flow rate of 0.5 mL per minute. The 
fractions containing the refined protein were pooled and a total of 10 μL was loaded onto 
a 15% SDS-PAGE gel. Fractions containing the higher molecular weight contaminant 
were also processed as above and 10 μL was loaded onto the gel.  After confirming the 
presence of the desired protein at the proper void volume, without the high molecular 
weight contaminant, the pooled fractions were concentrated using a 10 kDa molecular 
weight cut-off Amicon Ultra Centrifugal device, (Milipore, Billerica, MA) by centrifuging at 
4,000 g for 20-30 minutes at 4 °C. The two step dialysis was carried out as described in 
section 2.5.  The high molecular weight contaminant was removed from the size exclusion 
column. The resultant pure protein was used to carry out further activity assays.  
 
2.8 In vitro activity assays of purified APOBEC3H proteins 
To complement the genetic data obtained from the kanamycin resistance reversion 
assay, the partially purified GSTA3H200 and poly-histidine tagged A3H-183 (HisA3H183) 
was tested for their ability to deaminate cytosine in vitro. Essentially pure hisA3H183 
obtained from the size exclusion column was also tested. Four different 17-mers of DNA 
were used in the assay. The oligonucleotides were 5’ 6-FAM labeled and contains two 
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consecutive cytosines preceded by either A, G, T or C. The oligonucleotide used for a 
positive control contained ‘CCU’ sequence. All the oligonucletides were custom 
synthesized from Integrated DNA Technologies (San Jose, CA) and were PAGE purified 
prior to use. The sequences of the oligonucleotides are listed in Table 2. Briefly, 1 pmol of 
oligonucleotide was incubated with partially purified GSTA3H200 or hisA3H183 and 
incubated for two hours at 37 °C. The total reaction volume was 10 μL in the reaction 
buffer containing 40 mM Tris-HCl, pH 7.4, 5 mM EDTA, 1 mM DTT and 40 mM NaCl. One 
unit of E. coli UDG (New England Biolabs, Ipswich, MA) was added with the UDG reaction 
buffer (20 mM Tris-HCl, pH 8, 1 mM EDTA, 1 mM DTT) and the reaction was continued at 
37 °C for one hour.  NaOH was added to a final concentration of 0.1 M and the reaction 
was heated for 5 minutes at 95 °C. An equal volume of formamide containing gel loading 
dye (95% formamide, 0.025% bromophenol blue, 5 mM EDTA) was added to the reaction 
mixture and the mixture was heated again for 5 minutes at 95 °C. The reaction was briefly 
spun down at 10,000 g for one minute and 10 μL was loaded onto a denaturing 20% 
DNA-PAGE gel. The gel was run in 1X TBE buffer at 90 V. The gel was scanned using 
Typhoon 9210 phosphorimager (GE Healthcare) with an excitation wavelength of 499 nm. 
The intensities of the substrates and the products were quantified using ImageQuant 
software. Percent conversion of the substrate was calculated per the equation: (intensity 
of the product band - intensity of the background) / ((intensity of the substrate band - 
intensity of the background) + (intensity of the product band - intensity of the 
background)). For the homogenous protein preparation of hisA3H183 obtained from size 
exclusion, different amounts were used for the activity assays. The assays were carried 
out as described above.  
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CHAPTER 3: RESULTS AND DISCUSSION 
The main objective of this project was to obtain a version of human APOBEC3H 
that is active, both in vivo and in vitro. To study the DNA cytosine deaminase activity, I 
used a novel E. coli mutator assay, the kanamycin resistance reversion assay.   
The kanamycin resistance reversion assay data for the 200 amino acid version of 
APOBEC3H (Figure 11) suggests that the APOBEC3H-200 is not an efficient DNA 
cytosine deaminase. Eight to twelve independent cultures were used to determine the 
median value of the kanamycin resistance reversion frequency of each population, 
including the negative control (empty vector). The median value of the kanamycin 
resistance reversion frequency of the splice variant APOBEC3H-200 was only ~3 fold 
(p=0.052) higher than the empty vector control.  
 
 
Figure 11: Kanamycin resistance reversion assay results for pSUA3H-200. 
                   The median value of the revertant frequency is shown by the horizontal bar.                                         
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To assess the in vitro biochemical activity, an N-terminally GST tagged version of 
A3H200 was obtained using glutathione affinity chromatography. Figure 12 represents the 
12% SDS PAGE gel with the protein fractions that were collected.  
 
Figure 12: 12% SDS-PAGE gel for GSTA3H200 purification. 
                    Lane 1 : Molecular weight marker, Lane 2 : CFL, Lane 3 : Flow-through,  
                  Lane 4 : wash, Lanes 5-10 : eluates of GSTA3H200 (boxed) 
 
 
The expected protein size of GSTA3H200 was ~48 kDa, which was not 
significantly over-expressed. Thus, a Western blot was carried out using anti-GST mouse 
primary antibody. As presented in Figure 12, the protein seems to be expressed, with 
smaller molecular weight degradation products.  The activity assay was performed as 
described above using concentrated eluates obtained from the affinity column. A total of 
1.5 µg of protein did not give any cleaved DNA product (Figure 14).    
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Figure 13: Western blot for GSTA3H200 
                  Lane 1: Molecular weight marker, Lane 2: Eluate from GST affinity column. 
 
 
Figure 14: DNA cytosine deaminase activity assay for partially purified GSTA3H200 
 
As human APOBEC3H is a known DNA cytosine deaminase, which contains a 
conserved zinc binding deaminase domain, we wanted to study the other splice variants 
of this enzyme. From a previous study by Harari et al. [53], the splice variant that encodes 
183 amino acids (hapI-GKE-183) displayed ~20 fold higher HIV-1 restriction potential than 
the other variants. To study the DNA cytosine deaminase efficiency of this splice variant, 
the kanamycin resistance reversion assay was carried out using the same conditions as 
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above. Interestingly, cells with the human APOBEC3H-183 showed higher kanamycin 
resistance revertant frequency than the empty vector control, although the value was not 
as high as the human APOBEC3A (Figure 15). Human APOBEC3A cloned in pSU24 has 
shown increased DNA cytosine deaminase activity in this assay [26]. The negative control 
was a catalytic mutant. APOBEC3AE72A. With increasing concentrations of IPTG, the 
revertant frequency was also higher. It is likely that higher IPTG concentrations result in 
greater expression of APOBEC3H and hence higher deamination activity. Addition of 
IPTG to a final concentration of 100 μM increased the kanamycin resistance reversion 
frequency ~10 fold.  
 
Figure 15: Kanamycin resistance reversion assay results for pSUA3H183. 
                  The median value is shown by the horizontal bar. 
 
To complement the genetic data obtained from the E. coli mutator assay, the 
activity of the APOBEC3H-183 was tested in vitro using purified proteins. As the first step 
in carrying out this in vitro activity assay, APOBEC3H-183 was purified as an N-terminally 
poly-histidine tagged APOBEC3H-183 (His-A3H183) using nickel affinity chromatography. 
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The SDS-PAGE gel is shown in Figure 16. The crude preparation of protein obtained from 
a 500 mL of culture was used to carry out the activity assay. 
 
Figure 16: 15% SDS-PAGE gel for nickel affinity purified APOBEC3H-183. 
Lane 1: Molecular weight marker, Lane 2: Flow-through, Lane 3: wash 1, Lane                  
4: wash 2, Lane 5: wash 3, Lane 6-7: eluate. The expected size of his-A3H-183 (~23 kDa) 
is boxed. A higher molecular weight contaminant is indicated by an arrow to the right. 
 
To confirm the overexpression of the poly-histidine tagged A3H183, a Western blot 
was carried out using mouse anti-his tag primary antibody. As shown in Figure 17 (lane 
9), the correct size of the protein was detected (~23 kDa). This result confirmed that 
sufficient protein expression in the soluble fraction of the lysate occurred. Unfortunately, a 
significant amount of the protein was lost and cleared through the wash and flow-through 
steps, perhaps due to insufficient binding to the nickel beads. This step needs further 
optimization. 
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Figure 17: Western blot for protein fractions obtained in nickel affinity purification. 
Lane 1: Molecular weight marker, Lane 2: Cell-free lysate, Lane 3: flow-                                                                                                    
though, Lane 4: wash 1, Lane 5: wash 2, Lane 6: wash 3, Lane 7-8: empty, Lane 9: 
eluate. The expected protein size of his-APOBEC3H-183 (~23 kDa) is boxed. 
 
We next carried out the in vitro biochemical activity assay using the partially 
purified APOBEC3H-183, described in [68] and [69]. Briefly, an event of DNA cytosine 
deamination in a single-stranded oligonucleotide will generate uracil. Incubation the 
olionucleotide with UDG, excises uracil and generates an abasic site. Treatment with 0.1 
M NaOH and heating to 95 °C (hot alkaline treatment), cleaves the phosphodiester 
backbone at the abasic site and introduces a single strand break, resulting in a shorter 
product. The appearance of this shorter product indicates a positive result or a proficient 
DNA cytosine deaminase activity of the enzyme tested. The corresponding 20% DNA-
PAGE gels are shown in Figures 18 and 19, for assays carried out using the partially 
purified N-terminal poly-histidine tagged APOBEC3H. The different reactions in each lane 
are indicated. The appearance of two product bands is attributed to the two deamination 
events in the consecutive cytosines in the substrate. As seen clearly, the appearance of 
the shorter product and the complete or partial disappearance of the substrate, 
corresponding to the amount of enzyme, indicates that the enzyme is active under the 
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conditions used. The lanes corresponding to the positive and negative controls are 
indicated. Although the yield was low, the protein preparation was active and was able to 
deaminate the cytosines in the oligonucleotide. The ‘CCC’ and ‘TCC’ substrates (1 pmol 
each) were converted 100% to product by 1 µg of the protein. Only ~35% of the substrate 
was converted in the ‘ACC’ oligomer. Approximately 65% of the ‘GCC’ substrate was 
converted to product under the same conditions. By averaging the four conversions, the 
specific activity of the enzyme was calculated to be >0.0125 pmol/µg/min under the 
specified conditions, suggesting that the enzyme is active, but has a slow turnover. For 
the ‘CCC’ oligo, the specific activity was >0.017 pmol/µg/min. 
 
Figure 18: Biochemical activity assay for partially purified APOBEC3H-183. 
‘CCC’ and ‘TCC’ oligomers were used. Lane 1 and lane 2 represent the negative and 
positive controls, respectively. The sequences of the substrate oligonucleotides are 
indicated in Table 2.  
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Figure 19: Biochemical activity assay for partially purified APOBEC3H-183. 
‘ACC’ and ‘GCC’ oligomers were used. Lane 1 and lane 2 represent the negative and 
positive controls, respectively. The sequences of the substrate oligonucleotides are 
indicated in Table 2. 
 
In order to further characterize the structure and the catalytic mechanism of the 
human APOBEC3H hap I GKE sv-183, essentially homogeneous preparation of the active 
enzyme is required. As the first step, the partially purified protein (his6-A3H-183) was 
further refined using size exclusion chromatography. The fractions obtained from the size 
exclusion column were concentrated using centrifugal devices and analyzed on a 15% 
SDS-PAGE gel. As shown in the chromatogram (Figure 20), the ~100 kDa contaminant 
was removed by the size exclusion column. Nearly pure protein was obtained (Figure 21), 
even though the yield was poor. Varying amounts of the protein were used to carry out the 
in vitro activity assay (Figure 22). 
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Figure 20: Size exclusion chromatogram. 
                  The peak corresponding for ~23 kDa is indicated by the arrow.      
 
 
Figure 21: SDS-PAGE gel (15%) with APOBEC3H-183 from a size exclusion column. 
Lane 1: Molecular weight marker, Lane 2: Cell free lysate, Lane 3: Flow-through, Lane 4: 
wash 1, Lane 5: wash 2, Lane 6: Eluate from nickel affinity column, Lane 7: concentrated 
fractions corresponding to ~23 kDa from the size exclusion column, Lane 9: Higher 
molecular weight contaminant from size exclusion column. 
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Figure 22 shows the 20% DNA-PAGE gel from the cytosine deaminase activity assay 
that was carried out using the fully purified his6-APOBECH-183. Increasing amounts of the 
enzyme were used. Only 45 ng of enzyme was able to deaminate ~70% of the substrate. 
For 100% activity, >0.1 µg of the protein was sufficient. The amount of enzyme in the 
reaction directly correlated to the activity in a 2 hour incubation. The specific activity of the 
enzyme is increased to ~0.13 pmol/µg/min. 
 
Figure 22: DNA cytosine deaminase activity assay of his-APOBEC3H-183.  
                  Different amounts of the protein were used in the assay, as indicated. 
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CHAPTER 4: CONCLUSIONS AND FUTURE DIRECTIONS 
 To obtain biochemically valid conclusions and to study structure-activity relationship, 
isolation of catalytically active proteins is necessary. Human APOBEC3H is a good 
example to study the evolution and positive selection of proteins. As the APOBEC3H 
shows human population-specific distribution and several splice variants, further 
biochemical characterization of multiple variants are required. In addition, identification of 
other cellular partners that interact with this enzyme is crucial for functional analysis. High 
resolution crystal and NMR structures of human APOBEC3H have not been obtained. I 
have cloned human APOBEC3H hapI-GKE splice variant 183 as an N-terminally poly-
histidine tagged version into a pET28 vector and purified it using nickel affinity and size 
exclusion chromatography, as the first step in characterizing the biochemical properties of 
this enzyme. Purified enzyme was tested for its DNA cytosine deaminase activity. The 
protein was efficient in deaminating cytosine in vitro. Further work is required to obtain the 
enzymatic parameters, such as catalytic efficiency. In addition, the calatytically-null mutant 
of human APOBEC3H, E56A [70] needs to be isolated and tested in vitro. The work in this 
project needs to be extended to obtain human APOBEC3H-183 in higher yields to 
characterize it biochemically and structurally. The catalytic mechanisms of the variants 
can also be evaluated from the structures obtained with suitable DNA substrates.  
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 The AID/APOBEC enzymes are DNA/RNA cytosine deaminases with important 
functions in innate and adaptive immunity. APOBEC3 enzymes play a crucial role in 
restricting the replication of exogenous retroviruses such HIV-1 and endogenous 
retrotransposition events. In particular, APOBEC3 enzymes have evolved in humans by 
gene duplication to compose seven members. APOBEC3H is highly diverse in its allelic 
sequence and the distribution is population-specific. It has evolved under strong positive 
selection over millions of years. To study the catalytic mechanism, structure, function and 
the underlying cause of its high diversity, a high resolution crystal or NMR structure is 
required are not yet available. The human APOBEC3H splice variant 183 was purified as 
an N-terminally poly-histidine tagged construct and it was tested for biochemical activity 
as the first step in characterizing the enzyme. 
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